In the meantime, we are actively developing a new small‐molecule inhibitor of ASPM for treating RT‐resistant disease, an effort that is expected to have important implications for improving the diagnosis and treatment of patients with RT‐resistant NSCLC. This evidence concerns the gene ASPM and non-small cell lung carcinoma.